Australia markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
27.49+0.95 (+3.58%)
At close: 04:00PM EDT
27.49 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close26.54
Open26.78
Bid27.45 x 1200
Ask27.49 x 1100
Day's range26.12 - 27.86
52-week range14.65 - 36.42
Volume834,254
Avg. volume466,120
Market cap1.46B
Beta (5Y monthly)1.76
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

    XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022 Company-sponsored Phase 2 Clinical Trial Initiated to Evaluate XEN1101 for the Treatment of MDD Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ende

  • GlobeNewswire

    Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update

    BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, May 10, 2022. Conference Call/Webcast Information: Date:Tuesday, May 10, 2022 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Dial-In Number:855-779-9075 International Dial-In:631-485-4866 Conference ID:2263884

  • GlobeNewswire

    Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)

    BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the initiation of a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical study – called the “X-NOVA” clinical trial – to evaluate the safety, tolerability, and efficacy of XEN1101 in Major Depressive Disorder (MDD). Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We are excited to announ